This study will evaluate the safety, tolerability, and anti-tumor activity of amivantamab SC as monotherapy and in addition to pembrolizumab or paclitaxel in participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Sid Sheth
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Head and Neck)
24-0434